血漿分餾的全球市場的預測(～2030年)

預計在預測期內，全球血漿分離市場規模將以 9.1% 的複合年增長率健康成長。

地區性分析

2022年北美市場佔最大市場佔有率。這是由於各種遺傳疾病的流行、人口老化的增加以及該地區醫療保健的擴大使用所造成的。由於免疫缺陷和衰弱疾病在該地區日益佔主導地位以及人們對這些框架的興趣日益濃厚，歐洲市場佔了第二大市場佔有率。

由於該地區免疫系統疾病的流行，預計中東、非洲和拉丁美洲市場將出現發展。

本報告提供全球血漿分餾市場相關調查分析，提供市場動態，地區和市場區隔的分析，企業簡介等資訊。

目錄

第1章 摘要整理

• 全球血漿分餾市場:各產品類型
• 全球血漿分餾市場:各用途
• 全球血漿分餾市場:各終端用戶
• 全球血漿分餾市場:各地區

第2章 市場簡介

第3章 調查手法

第4章 市場動態

• 促進因素
  • 免疫球蛋白在各治療領域的使用不斷增加
  • 血漿衍生產品的需求推動市場成長
  • 促進因素影響分析
• 抑制因素
  • 重組療法作為血漿衍生產品替代品的興起抑制了市場成長
  • 抑制因子影響分析
• 機會
  • 促進市場成長的主要企業的新技術發表

第5章 市場要素的分析

• 供應鏈分析
• 波特的五力分析模式
• 血漿分餾市場上主要低溫運輸產品/設備
• 對全球血漿分餾市場上COVID-19影響
  • 供應鏈的影響
  • 生產的影響
  • 地區的影響
  • 供需缺口的影響的分析
  • 價格的影響

第6章 全球血漿分餾市場:各產品類型

• 概要
• 免疫球蛋白
  • 靜脈注射免疫球蛋白
  • 皮下注射用免疫球蛋白
  • 其他
• 濃縮凝血因子
  • 第八凝血因子
  • 第九凝血因子
  • 血友病因子
  • 濃縮凝血素原複合體
  • 濃縮纖維蛋白原
  • 凝血因子XIII
• 白蛋白
• 蛋白分解酵素抑制劑
• 其他

第7章 全球血漿分餾市場:各用途

• 概要
• 免疫
• 神經
• 血液
• 重症加護
• 呼吸系統
• 風濕
• 血液腫瘤
• 其他

第8章 全球血漿分餾市場:各終端用戶

• 概要
• 醫院·診療所
• 臨床研究機關
• 學術機構
• 其他

第9章 全球血漿分餾:各地區

• 概要
• 北美
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 其他的歐洲
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 其他的亞太地區
• 其他地區
  • 南美
  • 中東
  • 非洲

第10章 競爭情形

• 競爭概要
• 全球血漿分餾市場上主要成長策略
• 競爭基準

第11章 企業簡介

• CSL BEHRING
• GRIFOLS THERAPEUTICS
• BAXTER INTERNATIONAL INC.
• MITSUBISHI TANABE
• TAKEDA PHARMACEUTICAL
• OCTAPHARMA AG
• HUALAN BIO
• KEDRION S.P.A
• LFB GROUP
• BIOTEST AG

Market Overview

The Plasma Fractionation Market is expected to register a healthy CAGR of 9.1% during the forecast period. The creating use of immunoglobulins for various supportive regions and interest in plasma-deduced restorative things drive the market advancement driving market improvement.

Immunoglobulins are used as first-line treatment for various neurologic, immunologic, and hematologic conditions. To some degree as of late, the finding speed of various immunological diseases has extended in view of mechanical types of progress. The creation inherited assessment for portraying and diagnosing immunodeficiency will similarly extend the clinical necessity for immunoglobulins in view of the extended number of dissected patients. Moreover, the inescapability of unprecedented and safe framework diseases and an extension in immunology research by and large are further driving the advancement of this part. According to data circulated by the Public Spot for Advancing Translational Sciences in February 2022, there are about 7,000 to 10,000 unprecedented ailments impacting individuals, of which a few hundred have any treatment. Further, the rising number of captivating diseases is adding to the advancement of the immunoglobulin market area.

Market Segmentation

The Market segments of Plasma Fractionation, based on product type, include immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others.

The Plasma Fractionation Market based on Application is classified into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others. Based on an end-user the market is segmented into hospitals and clinics, clinical research laboratories, academic institutes, and others.

Regional Insights

The North American plasma fractionation market represented the biggest market share in 2022. This is because of the rising pervasiveness of different hereditary sicknesses, the developing geriatric populace, and expanding medical care use in the region. The high commonness of Alzheimer's illness and the viability of the plasma fractionation item in the treatment support the market development over the gauge period. Europe plasma fractionation market represents the second-biggest market share because of the rising predominance of immunodeficiency and draining issues in the region and expanding interests in these frameworks.

The Asia-Pacific plasma fractionation market is supposed to develop at a critical offer from 2023 to 2032. This is because of an expansion out in the open and confidential subsidizing for innovative work, great unofficial laws, expanded utilization of immunoglobulins, rising commonness of target illnesses with a maturing populace with blood-related sicknesses, and rising plasma-based therapy reception in the Asia-Pacific region.

The Rest of the World is fragmented into the Center East, Africa, and Latin America. plasma fractionation market in the previously mentioned regions is probably going to observe development because of the commonness of immune system illnesses in the regions. In addition, The Assembled Bedouin Emirates (UAE), Saudi Arabia, and South Africa are the 3 significant nations in the MEA.

Major Players

Key Companies in the market of Plasma Fractionation are CSL Behring (US), Grifols Therapeutics (Spain), Baxter International Inc (US), Hualan Bio (China), Mitsubishi Tanabe (Japan), Takeda Pharmaceutical (Japan), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), LFB Group (France), and Biotest AG (Germany).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1.1 GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE
• 1.1.2 GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION
• 1.1.3 GLOBAL PLASMA FRACTIONATION MARKET, BY END USER
• 1.1.4 GLOBAL PLASMA FRACTIONATION MARKET, BY REGION

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 SCOPE OF THE STUDY
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 RESEARCH PROCESS
• 3.2 PRIMARY RESEARCH
• 3.3 SECONDARY RESEARCH
• 3.4 MARKET SIZE ESTIMATION
• 3.5 TOP DOWN & BOTTOM-UP APPROACH
• 3.6 FORECAST MODEL
• 3.7 LIST OF ASSUMPTIONS

4 MARKET DYNAMICS

• 4.1 DRIVERS
  • 4.1.1 GROWING USE OF IMMUNOGLOBULINS FOR VARIOUS THERAPEUTIC AREA
  • 4.1.2 DEMAND FOR PLASMA DERIVED MEDICINAL PRODUCTS DRIVES THE MARKET GROWTH
  • 4.1.3 DRIVER IMPACT ANALYSIS
• 4.2 RESTRAINTS
  • 4.2.1 EMERGENCE OF RECOMBINANT THERAPIES AS AN ALTERNATIVE TO PLASMA DERIVED MEDICINES RESTRAINTS THE MARKET GROWTH
  • 4.2.2 RESTRAINT IMPACT ANALYSIS
• 4.3 OPPORTUNITIES
  • 4.3.1 LAUNCH OF NEW TECHNOLOGIES BY KEY PLAYERS TO AUGMENT MARKET GROWTH

5 MARKET FACTOR ANALYSIS

• 5.1 SUPPLY CHAIN ANALYSIS
  • 5.1.1 RAW APPLICATIONS
  • 5.1.2 MANUFACTURES
  • 5.1.3 DISTRIBUTION
  • 5.1.4 END USER
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 MAJOR COLD CHAIN PRODUCTS/DEVICES IN THE PLASMA FRACTIONATION MARKET
• 5.4 IMPACT OF COVID-19 ON THE GLOBAL PLASMA FRACTIONATION MARKET
  • 5.4.1 IMPACT ON SUPPLY CHAIN
  • 5.4.2 IMPACT ON PRODUCTION
  • 5.4.3 IMPACT ON REGIONS
  • 5.4.4 IMPACT ON DEMAND-SUPPLY GAP ANALYSIS
  • 5.4.5 IMPACT ON PRICING

6 GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE

• 6.1 OVERVIEW
• 6.2 IMMUNOGLOBULIN
  • 6.2.1 Intravenous Immunoglobulins
  • 6.2.2 Subcutaneous Immunoglobulins
  • 6.2.3 Others
• 6.3 COAGULATION FACTOR CONCENTRATES
  • 6.3.1 Factor VIII
  • 6.3.2 Factor IX
  • 6.3.3 Von Willebrand Factor
  • 6.3.4 Prothrombin Complex Concentrate
  • 6.3.5 Fibrinogen Concentrates
  • 6.3.6 Factor XIII
• 6.4 ALBUMIN
• 6.5 PROTEASE INHIBITORS
• 6.6 OTHERS

7 GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 IMMUNOLOGY
• 7.3 NEUROLOGY
• 7.4 HEMATOLOGY
• 7.5 CRITICAL CARE
• 7.6 PULMONOLOGY
• 7.7 RHEUMATOLOGY
• 7.8 HEMATO-ONCOLOGY
• 7.9 OTHERS

8 GLOBAL PLASMA FRACTIONATION MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS & CLINICS
• 8.3 CLINICAL RESEARCH LABORATORIES
• 8.4 ACADEMIC INSTITUTES
• 8.5 OTHERS

9 GLOBAL PLASMA FRACTIONATION, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 ITALY
  • 9.3.4 SPAIN
  • 9.3.5 UK
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 JAPAN
  • 9.4.3 INDIA
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 LATIN AMERICA
  • 9.5.2 MIDDLE EAST
  • 9.5.3 AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 COMPETITIVE OVERVIEW
• 10.2 MAJOR GROWTH STRATEGY IN THE GLOBAL PLASMA FRACTIONATION MARKET
• 10.3 COMPETITIVE BENCHMARKING

11 COMPANY PROFILES

• 11.1 CSL BEHRING
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 GRIFOLS THERAPEUTICS
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 BAXTER INTERNATIONAL INC.
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 MITSUBISHI TANABE
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGIES
• 11.5 TAKEDA PHARMACEUTICAL
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 SWOT ANALYSIS
  • 11.5.6 KEY STRATEGIES
• 11.6 OCTAPHARMA AG
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 HUALAN BIO
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
• 11.8 KEDRION S.P.A
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
• 11.9 LFB GROUP
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
• 11.10 BIOTEST AG
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES

LIST OF TABLES

• TABLE 1 LIST OF ASSUMPTIONS
• TABLE 2 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 3 IMMUNOGLOBULIN: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 4 IMMUNOGLOBULIN: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 5 COAGULATION FACTOR CONCENTRATES: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 6 COAGULATION FACTOR CONCENTRATES: MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2032 (USD MILLION)
• TABLE 7 ALBUMIN: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 8 PROTEASE INHIBITORS: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 9 OTHERS: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 10 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 11 IMMUNOLOGY: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 12 NEUROLOGY: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 13 HEMATOLOGY: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 14 CRITICAL CARE: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 15 PULMONOLOGY: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 16 RHEUMATOLOGY: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 17 HEMATO-ONCOLOGY: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 18 OTHERS: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 19 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 20 HOSPITALS & CLINICS: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 21 CLINICAL RESEARCH LABORATORIES: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 22 ACADEMIC INSTITUTES: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 23 OTHERS: MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 24 GLOBAL PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY REGION, 2019-2032 (USD MILLION)
• TABLE 25 NORTH AMERICA: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2019-2032 (USD MILLION)
• TABLE 26 NORTH AMERICA: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 27 NORTH AMERICA MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 28 NORTH AMERICA PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 29 US: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 30 US MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 31 US PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 32 CANADA: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 33 CANADA MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 34 CANADA PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 35 EUROPE: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2019-2032 (USD MILLION)
• TABLE 36 EUROPE: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 37 EUROPE MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 38 EUROPE PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 39 GERMANY: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 40 GERMANY MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 41 GERMANY PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 42 FRANCE: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 43 FRANCE MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 44 FRANCE PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 45 ITALY: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 46 ITALY MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 47 ITALY PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 48 SPAIN: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 49 SPAIN MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 50 SPAIN PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 51 UK: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 52 UK MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 53 UK PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 54 REST OF EUROPE: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 55 REST OF EUROPE MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 56 REST OF EUROPE PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 57 ASIA-PACIFIC: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2019-2032 (USD MILLION)
• TABLE 58 ASIA PACIFIC: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 59 ASIA PACIFIC MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 60 ASIA PACIFIC PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 61 CHINA: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 62 CHINA MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 63 CHINA PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 64 JAPAN: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 65 JAPAN MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 66 JAPAN PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 67 INDIA: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 68 INDIA MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 69 INDIA PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 70 AUSTRALIA: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 71 AUSTRALIA MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 72 AUSTRALIA PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 73 SOUTH KOREA: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 74 SOUTH KOREA MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 75 SOUTH KOREA PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 76 REST OF ASIA PACIFIC: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 77 REST OF ASIA PACIFIC MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 78 REST OF ASIA PACIFIC PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 79 REST OF THE WORLD: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2019-2032 (USD MILLION)
• TABLE 80 REST OF WORLD: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 81 REST OF WORLD MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 82 REST OF WORLD PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 83 LATIN AMERICA: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 84 LATIN AMERICA MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 85 LATIN AMERICA PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 86 MIDDLE EAST: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 87 MIDDLE EAST MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 88 MIDDLE EAST PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 89 AFRICA: MARKET ESTIMATES, BY PRODUCT TYPE, 2019-2032 (USD MILLION)
• TABLE 90 AFRICA MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019-2032 (USD MILLION)
• TABLE 91 AFRICA PLASMA FRACTIONATION MARKET ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD MILLION)
• TABLE 92 CSL BEHRING: PRODUCTS OFFERED
• TABLE 93 CSL BEHRING: KEY DEVELOPMENTS
• TABLE 94 GRIFOLS, S.A: PRODUCTS OFFERED
• TABLE 95 GRIFOLS: KEY DEVELOPMENTS
• TABLE 96 BAXTER INTERNATIONAL INC.: PRODUCTS OFFERED
• TABLE 97 MITSUBISHI TANABE: PRODUCTS OFFERED
• TABLE 98 TAKEDA PHARMACEUTICAL: PRODUCTS OFFERED
• TABLE 99 OCTAPHARMA AG.: PRODUCTS OFFERED
• TABLE 100 HUALAN BIO: PRODUCTS OFFERED
• TABLE 101 KEDRION SPA: PRODUCTS OFFERED
• TABLE 102 LFB GROUP.: PRODUCTS OFFERED
• TABLE 103 BIOTEST AG: PRODUCTS OFFERED

LIST OF FIGURES

• FIGURE 1 MARKET SYNOPSIS
• FIGURE 2 GLOBAL PLASMA FRACTIONATION MARKET ANALYSIS, BY PRODUCT TYPE, 2022
• FIGURE 3 GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2022 & 2032 (USD MILLION)
• FIGURE 4 GLOBAL PLASMA FRACTIONATION MARKET ANALYSIS, BY APPLICATION, 2022
• FIGURE 5 GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION, 2022 & 2032 (USD MILLION)
• FIGURE 6 GLOBAL PLASMA FRACTIONATION MARKET ANALYSIS, BY END USER, 2022
• FIGURE 7 GLOBAL PLASMA FRACTIONATION MARKET, BY END USER, 2022 & 2032 (USD MILLION)
• FIGURE 8 GLOBAL PLASMA FRACTIONATION MARKET ANALYSIS, BY REGION, 2022
• FIGURE 9 GLOBAL PLASMA FRACTIONATION MARKET: STRUCTURE
• FIGURE 10 RESEARCH PROCESS OF MRFR
• FIGURE 11 DRO ANALYSIS OF GLOBAL PLASMA FRACTIONATION MARKET
• FIGURE 12 DRIVER IMPACT ANALYSIS
• FIGURE 13 RESTRAINT IMPACT ANALYSIS
• FIGURE 14 SUPPLY CHAIN: GLOBAL PLASMA FRACTIONATION MARKET
• FIGURE 15 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL PLASMA FRACTIONATION MARKET
• FIGURE 16 GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2022 (% SHARE)
• FIGURE 17 GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION, 2022 (% SHARE)
• FIGURE 18 GLOBAL PLASMA FRACTIONATION MARKET, BY END USER, 2022 (% SHARE)
• FIGURE 19 GLOBAL PLASMA FRACTIONATION MARKET, BY REGION, 2022 (% SHARE)
• FIGURE 20 GLOBAL PLASMA FRACTIONATION MARKET, BY REGION, 2022-2030 (USD MILLION)
• FIGURE 21 NORTH AMERICA: PLASMA FRACTIONATION SHARE, BY COUNTRY, 2022 (% SHARE)
• FIGURE 22 EUROPE: PLASMA FRACTIONATION SHARE, BY COUNTRY, 2022 (% SHARE)
• FIGURE 23 ASIA-PACIFIC: PLASMA FRACTIONATION SHARE, BY COUNTRY, 2022 (% SHARE)
• FIGURE 24 REST OF THE WORLD: PLASMA FRACTIONATION SHARE, BY COUNTRY, 2022 (% SHARE)
• FIGURE 25 CSL LIMITED: SWOT ANALYSIS
• FIGURE 26 GRIFOLS, S.A: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 27 GRIFOLS: SWOT ANALYSIS
• FIGURE 28 BAXTER INTERNATIONAL INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 29 BAXTER INTERNATIONAL INC.: SWOT ANALYSIS
• FIGURE 30 MITSUBISHI TANABE.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 31 MITSUBISHI TANABE.: SWOT ANALYSIS
• FIGURE 32 TAKEDA PHARMACEUTICAL: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 33 TAKEDA PHARMACEUTICAL.: SWOT ANALYSIS
• FIGURE 34 OCTAPHARMA.: SWOT ANALYSIS
• FIGURE 35 HUALAN BIO: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 36 KEDRION SPA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 37 BIOTEST AG: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 38 BIOTEST AG: SWOT ANALYSIS